ME Therapeutics Holdings Inc. METXF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 119.20K | 90.70K | 153.00K | 152.80K | 135.90K |
| Depreciation & Amortization | 19.90K | 20.60K | 19.00K | 19.40K | 18.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 317.70K | 241.10K | 273.60K | 292.50K | 256.50K |
| Operating Income | -317.70K | -241.10K | -273.60K | -292.50K | -256.50K |
| Income Before Tax | -290.00K | -210.50K | -253.90K | -246.70K | -251.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -290.00K | -210.50K | -253.90K | -246.70K | -251.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.00K | -210.50K | -253.90K | -246.70K | -251.40K |
| EBIT | -317.70K | -241.10K | -273.60K | -292.50K | -256.50K |
| EBITDA | -308.10K | -230.90K | -264.70K | -283.50K | -238.20K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 30.05M | 30.05M | 29.79M | 29.61M | 29.59M |
| Average Diluted Shares Outstanding | 30.05M | 30.05M | 29.79M | 29.61M | 29.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |